Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Biotechs: Still Well Placed For More Gains

9h seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-2)

VRTX / Vertex Pharmaceuticals Inc. 10-K (Annual Report)

2018-02-16 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from              to              Commission file number 000-19319 __________________________________

Updating My Bullish Views On Vertex Pharmaceuticals

2018-02-15 seekingalpha
VRTX is an emerging though large-cap biotech with a growing portfolio of drugs for cystic fibrosis. (15-0)

VRTX / Vertex Pharmaceuticals Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) VERTEX PHARMACEUTICALS INC / MA (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92532F100 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

VRTX / Vertex Pharmaceuticals Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) VERTEX PHARMACEUTICALS INC / MA (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92532F100 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal

2018-02-14 reuters
* VERTEX ANNOUNCES TREATMENT WITH THE NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF ACUTE PAIN IN PHASE 2 STUDY

Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment

2018-02-14 seekingalpha
Today we will focus on Akebia Therapeutics (AKBA) after the company provided an update to investors on its late-stage vadadustat studies. (252-3)

Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

2018-02-13 zacks
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) announced that the FDA has granted approval to its cystic fibrosis (CF) corrector, tezacaftor (VX-661), in combination with ivacaftor (Kalydeco) under the brand name, Symdekotm. The combo therapy is approved to treat the underlying cause of CF in patients aged 12 years and above with certain mutations in the CF transmembrane conductance regulator gene. (52-0)

Vertex Just Keeps On Impressing The Street With Regulatory Approvals

2018-02-13 seekingalpha
Vertex obtains FDA approval for Symdeko treating patients with cystic fibrosis two weeks ahead of schedule.

VRTX / Vertex Pharmaceuticals Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 3 VERTEX PHARMACEUTICALS INC COMMON STOCK Cusip #92532F100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #92532F100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,925,680 Item 6: 0 Item 7: 16,923,002 Item 8: 0 Item 9: 16,923,002 Item 11: 6.

VRTX / Vertex Pharmaceuticals Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 3 VERTEX PHARMACEUTICALS INC COMMON STOCK Cusip #92532F100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #92532F100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,925,680 Item 6: 0 Item 7: 16,923,002 Item 8: 0 Item 9: 16,923,002 Item 11: 6.

UPDATE 1-U.S. FDA approves Vertex cystic fibrosis combination treatment

2018-02-12 reuters
Feb 12 (Reuters) - The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc’s Kalydeco with another medicine, Vertex said, marking the company’s third product for the life-shortening lung disorder.

BRIEF-Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis

2018-02-12 reuters
* VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK)

VRTX / Vertex Pharmaceuticals Inc. 8-K (Current Report)

2018-02-12 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2018 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 000-19319 (Commission File Number) 04-3039129 (IRS Employer Identification No.

BRIEF-Vertex Pharma Says FDA Approved SYMDEKO For Treating Underlying Cause Of Cystic Fibrosis

2018-02-12 reuters
* VERTEX PHARMACEUTICALS INC - FDA APPROVED SYMDEKO FOR TREATING UNDERLYING CAUSE OF CYSTIC FIBROSIS IN PEOPLE AGES 12 AND OLDER​


CUSIP: 92532F100